Court Place Advisors LLC boosted its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 20,661 shares of the biopharmaceutical company’s stock after buying an additional 1,445 shares during the period. Court Place Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,317,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Tradewinds Capital Management LLC raised its holdings in Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the period. Atlantic Trust LLC purchased a new stake in Bristol-Myers Squibb during the 2nd quarter valued at $111,000. AllSquare Wealth Management LLC purchased a new stake in Bristol-Myers Squibb during the 3rd quarter valued at $134,000. Blue Chip Partners Inc. raised its holdings in Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the period. Finally, Shine Investment Advisory Services Inc. raised its holdings in Bristol-Myers Squibb by 166.3% during the 3rd quarter. Shine Investment Advisory Services Inc. now owns 2,170 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 1,355 shares during the period. Institutional investors own 69.67% of the company’s stock.
In other news, Director Theodore R. Samuels II purchased 4,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were acquired at an average price of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the previous year, the company posted $0.77 EPS. Bristol-Myers Squibb’s quarterly revenue was up 6.7% compared to the same quarter last year. equities research analysts expect that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a dividend of $0.40 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.99%.
Several research firms recently weighed in on BMY. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Thursday, October 26th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective on the stock. in a research report on Friday, December 22nd. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Jefferies Group downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective on the stock. in a research report on Monday, October 16th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $65.05.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.